First-Line Treatments for Advanced Clear Cell RCC
A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.
Stay updated with breaking news from Risk Stratification. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.
For chimeric antigen receptor T-cell therapies (CAR T) approved to treat B-cell lymphoproliferative disorders and multiple myeloma, more data are needed on the effects of posttreatment myeloid neoplasms to optimize patient counseling, risk stratification, and surveillance.
Mikkael A. Sekeres, MD, MS, discusses the influence of therapeutic developments and conflicting classification systems on the management of MDS.
As the healthcare sector evolves, the focus on risk stratification, as demonstrated by North Carolina's HOP, is crucial for advancing VBC.
Practical guidance for institutions navigating bispecific therapy integration without prior experience is provided.